

TruSight™ Autism Sequencing Panel

Using expert-defined content and proven next-generation sequencing technology to efficiently and cost-effectively assist in the evaluation of characteristics associated with Autism Spectrum Disorders (ASDs).

Highlights

- **Expert Defined Content**
Targeting 101 genes implicated in ASDs
 - **Low Input DNA Requirement**
Excellent data quality with as little as 50 ng DNA to preserve precious samples
 - **Fast, Simple Workflow**
Library preparation and enrichment completed in 1.5 days

Anti-Social


that usually appear in young children under the age of three. It is the fastest growing serious developmental disability in the United States, affecting 1 in 88 children¹. ASDs are typically characterized by social/communication deficits and repetitive behaviors. Early intervention with behavioral therapies has been proven to improve learning, communication, and social skills. This makes it essential to find a method for evaluating characteristics associated with ASDs as early as possible.

include a genetic component. The TruSight™ Autism Sequencing Panel provides pre-designed, ready-to-use oligos targeting 101 developmental delay genes implicated with ASDs. The sequencing panel is compatible with TruSight Rapid Capture that takes advantage of Nextera® Rapid Capture technology to offer a single, integrated library preparation and enrichment workflow that can be completed in just 1.5 days (Figure 1). Delivering excellent data quality from low sample input (50 ng), TruSight Autism and TruSight Rapid Capture enable efficient and reliable analysis of precious samples, while retaining sufficient material for future analyses.

Developed in collaboration with Dr. Jo
st Kennedy Krieger Institute (KKI), Ta

implicated with ASDs. The sequencing panel includes genes reported in the Online Mendelian Inheritance in Man (OMIM) database on autism; genes with recurrent mutations suspected in developmental delays²⁻⁴; genes with reported mutations as found in case studies involving developmental delay characteristics; genes from other publicly available ASD panels; and genes from summaries of ASD-relevant genes (e.g., ASDKB⁴). Genes neighboring strong association signals were excluded in the absence of published reports of mutations.

Figure 1. Integrated Workflow



* For higher throughput, use NextSeq™ flow cells on the NextSeq system or HiSeq® flow cells on the HiSeq system.

Digitized by srujanika@gmail.com

TruSight Autism features a h

The kit includes > 4,500 80-mer probes, each constructed against the human NCBI37/hg19 reference genome. The probe set was designed to enrich for 1,728 exons, spanning 101 genes of interest (Table 1).

TruSight Autism targets a total of 328 Kb of the human genome. The 80-mer probes target the coding regions of approximately 500 loci (containing

of 300 bp), enriching 350–650 bases centered symmetrically around the midpoint of the probe (Figure 2)⁵. This means that the kit provides coverage of exonic and non-coding DNA in exon-flanking regions, on average 50 bp.

TruSight Autism and TruSight Rapid Capture leverage Nextera library preparation technology. By eliminating

Mechanical DNA fragmentation and introducing a unique multiplex

Data Sheet: DNA Sequencing

- Table 1: Coverage Details

Cumulative target region size	328 Kb
Number of target genes	101
Number of target exons	1,728
Probe size	80-mer
Number of probes	> 4,500
Recommended mean coverage	100x
Target minimum coverage	20x
Percent exons covered based on coverage metrics	≥ 95%

Figure 2: Probe Footprint



With an approximately 300 bp DNA library (insert size of 300 bp), the probe will enrich 350–650 bp centered around its midpoint.

Figure 3: Integration of light and dark matter





Figure 4: High Coverage Uniformity



prepared and then simultaneously enriched using the IruSight Rapid Capture Kit along with the IruSight Autism Sequencing Panel. Samples were sequenced across MiSeq flow cells, generating mean read depths of 100–300 \times (varying for each sample). Over 95% of bases (> 300 Kb) were covered at 0.2 \times mean coverage.

reduces hands-on time for a high-throughput workflow that saves at least one full day over all other currently available enrichment workflows (Figure 1). Furthermore, master-mixed reagents are coupled with a plate-based protocol for simultaneous processing of up to 24 enrichment reactions (288 total samples).

Flexible kit configurations enable labs to readily meet their sample

throughput needs. For those requiring higher throughput, kit reagent volumes are optimized for liquid handlers to make an automation-friendly workflow. TruSight Rapid Capture kits supporting lower throughput options are also available, allowing labs to cost-effectively run samples immediately instead of waiting to batch.

Following the TruSight workflow, the process starts with rapid Nextera library preparation and sequencing on the Illumina® DNA Sequencing Platform.

adapter-tagged libraries (Figure 3A). This rapid prep requires only 50 ng of input DNA and takes less than 3 hours for a plate of 96 samples. Nextera fragmentation of DNA simultaneously fragments and tags DNA without the need for mechanical shearing. Integrated sample barcodes then allow the pooling of up to 96 samples for a single Rapid Capture pull down. Next, libraries are denatured into single-stranded DNA (Figure 3B) and biotin-labeled probes specific to the targeted region are used for the Rapid Capture hybridization (Figure 3C). The pool is enriched for the desired regions by adding streptavidin beads that bind to the biotinylated probes (Figure 3D). Biotinylated DNA fragments bound to the streptavidin beads are magnetically pulled down from the solution (Figure 3E). The enriched DNA fragments are then eluted from the beads and hybridized for a second Rapid Capture. This entire process is completed in only 1.5 days, enabling a single researcher to efficiently process up to 288 samples at one time—all without automation.

Sequence data gene

are analyzed by the On-Instrument MiSeq Reporter (MSR) software. After demultiplexing and FASTQ file generation, the software uses the Burrows-Wheeler Aligner (BWA) to align the reads against the hg19 homo sapiens reference genome to create BAM files. The Genome Analysis Toolkit (GATK) is then used to perform variant analysis for the target regions specified in the manifest file. The output of GATK are VCF files, which are text files that contain SNPs, indels, and other structural variants.

With TruSight Autism and

pooled multisample libraries. Each sample is sequenced with high coverage uniformity across the target region, with $\geq 95\%$ of exons covered at a minimum coverage of $0.2\times$ of the mean coverage (Figure 4). This uniformity applies to smaller exons (< 150 bp) as well as long coding exons.

The Trustlight A
access an exp

genomic features associated with ASDs. The optimized probe set provides comprehensive coverage of the targeted regions with high coverage uniformity for identifying variants. Combining this content with the TruSight enrichment method enables a fast, easy workflow, requiring low sample DNA input, generating a highly efficient targeted resequencing solution for early detection of ASD genetic characteristics.

Data Sheet: DNA Sequencing

Ordering Information

Product	Catalog No.	TG Catalog No.*
TruSight Autism Sequencing Panel (4 enrichments)	FC-121-0203	TG-141-1003
Rapid Capture Kits		
TruSight Rapid Capture Kit (1 index, 8 samples)	FC-140-1101	TG-140-1101
TruSight Rapid Capture Kit (2 indices, 8 samples)	FC-140-1102	TG-140-1102
TruSight Rapid Capture Kit (4 indices, 16 samples)	FC-140-1103	TG-140-1103
TruSight Rapid Capture Kit (24 indices, 48 samples)	FC-140-1104	TG-140-1104
TruSight Rapid Capture Kit (24 indices, 96 samples)	FC-140-1105	TG-140-1105
TruSight Rapid Capture Kit (96 indices, 288 samples)	FC-140-1106	TG-140-1106

* TG-labeled consumables include features intended to help customers reduce the frequency of revalidation. They are available only under supply agreement and require customers to provide a binding forecast. TruSight sequencing panels are available for evaluation purposes prior to executing a supply agreement. Please contact your account manager for more information.

Learn More

To learn more about the TruSight Autism Sequencing Panel, TruSight Rapid Capture kits, and Illumina next-generation sequencing technology, visit www.illumina.com/trusightautism.

References

1. Autism Speaks (www.autismspeaks.org/what-autism/facts-about-autism)
2. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al. (2008) Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82(2): 477–488.
3. Talkowski ME, Rosenfeld JA, Blumenthal I, Pillalamarri V, Chiang C, et al. (2012) Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 149(3): 525–537.
4. Vendeweyer G and Kooy RF (2009) Balanced translocations in mental retardation. Hum Genet 126(1): 133–147.
5. Optimizing Coverage for Targeted Resequencing Technical Note. (www.illumina.com/documents/products/technotes/technote_optimizing_coverage_for_targeted_resequencing.pdf)

Note regarding biomarker patents and other patents unique to specific uses of products.

Some genomic variants, including some nucleic acid sequences, and their use in specific applications may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.

Illumina • 1.800.809.4566 toll-free (U.S.) • +1.858.202.4566 tel • techsupport@illumina.com • www.illumina.com

FOR RESEARCH USE ONLY

© 2013–2014 Illumina, Inc. All rights reserved.

Illumina, IlluminaDx, BaseSpace, BeadArray, BeadXpress, cBot, CSPro, DASL, DesignStudio, Eco, GAIx, Genetic Energy, Genome Analyzer, GenomeStudio, GoldenGate, HiScan, HiSeq, Infinium, iSelect, MiSeq, Nextera, NextSeq, NuPCR, SeqMonitor, Solexa, TruSeq, TruSight, VeraCode, the pumpkin orange color, and the Genetic Energy streaming bases design are trademarks or registered trademarks of Illumina, Inc. All other brands and names contained herein are the property of their respective owners. Pub. No. 670-2012-014 Current as of 19 November 2014

